ENTITY
SMARTSCORE: 2.8/5
BeOne

BeOne (ONC US)

151
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
bullishBeOne
03 Jul 2025 22:11Broker

BeiGene (ONC US) - CDK4i Showed Preliminary Efficacy While Data Still Maturing

BeOne’s CDK4 inhibitor (BGB-43395) shows a favorable hematologic safety profile, supported by improved CDK4/CDK6 selectivity that reduces off...

Logo
351 Views
Share
bullishBeiGene
14 May 2025 07:15

Quiddity Leaderboard Hang Seng Index Jun25: Beigene Is Our Top Pick

We expect the ADDs/DELs and indicative weights for the Hang Seng Index to be publicly confirmed on Friday 16th May 2025. This is a good time to...

Logo
1.2k Views
Share
bullishBeiGene
11 May 2025 01:32

China Healthcare Weekly (May11)-Trump's Executive Order, Pharmacy's Risks, BeiGene 25Q1 Result Is Ok

​Trump aims to boost US drug manufacturing by reducing regulatory barriers, leading to industry changes. VBP will accelerate pharmacy closures....

Logo
457 Views
Share
bullishBeOne
09 May 2025 13:05Broker

BeiGene (ONC US) - First-Ever Quarterly GAAP Profit Marks Major Milestone

Sales of zanubrutinib remained strong. BeiGene reported product revenue of US$1.11bn in 1Q25 (+48% YoY, -1% QoQ), with zanubrutinib (Zanu)...

Logo
248 Views
Share
27 Jul 2025 02:05

HK Connect Flows Weekly (Jul 25th): China Life, China Mobile, CCB, Xiaomi, Kuaishou

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for China Life, China Mobile, CCB, Xiaomi, Kuaishou, China...

Logo
34 Views
Share
x